Mavatrep
 | |
| Clinical data | |
|---|---|
| Other names | JNJ-39439335 |
| Identifiers | |
| |
JSmol) | |
| |
| |
Mavatrep (JNJ‐39439335) is a TRPV1 receptor selective competitive antagonist.[1] It is an investigational analgesic that may be a potential treatment for pain and/or inflammation.
Phase I trials have been completed in healthy Japanese and Caucasian volunteers.[1][2]
Potential common adverse effects include thermohypoesthesia, chills, feeling cold, and feeling hot.[2]
Pharmacokinetics
When administered orally once a day, mavatrep reached steady-state in healthy volunteers in approximately 14 days.[2] It has a relatively long half life between 68 and 101 hours in Japanese subjects and between 82 and 130 hours in Caucasian subjects.[2]
Mavatrep is largely eliminated nonrenally. Mavatrep appears to be metabolized into two primary metabolites which are also eliminated nonrenally.[2]